Too Young for Breast Cancer? Not at this Conference
12 févr. 2019 07h00 HE
|
Young Survival Coalition
New York, NY, Feb. 12, 2019 (GLOBE NEWSWIRE) -- The Young Survival Coalition (YSC) will host more than 600 young breast cancer survivors, co-survivors and healthcare providers in Austin, Texas,...
Sermonix Pharmaceuticals to Present Three Posters Focused on Precision Medicine in the Treatment of Metastatic Breast Cancer at San Antonio Breast Cancer Symposium
14 nov. 2018 10h00 HE
|
Sermonix Pharmaceuticals LLC
Posters to be displayed at Dec. 4-8 conference address introduction of Phase 2 study of investigational drug lasofoxifene, its effect on breast cancer and lung and liver metastasis in an in vivo...
Sermonix Launches Phase 2 Trial to Evaluate Investigational Oral Lasofoxifene as a Targeted Precision Treatment for Women With ESR1 Mutations in Metastatic Breast Cancer
09 oct. 2018 10h00 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific...
Leaving a Legacy When You’re Young with Cancer
15 déc. 2017 08h00 HE
|
Young Survival Coalition
New York, NY, Dec. 15, 2017 (GLOBE NEWSWIRE) -- More than 250,000 women living in the U.S. today were diagnosed with breast cancer before their 41st birthday, and approximately 12,000 young women...
Cascadian Therapeutics Reports Third Quarter 2017 Financial Results
08 nov. 2017 16h01 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended...
Tucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 Congress
11 sept. 2017 06h00 HE
|
Cascadian Therapeutics, Inc.
Results from Pooled Analysis Support the Potential Utility of Tucatinib for Patients with HER2+ Metastatic Breast Cancer with Brain Metastases Data from Nonclinical Models Support Evaluation of...
2X Oncology Announces Validation of Drug Response Predictor (DRP) for its PARP Inhibitor 2X-121
09 août 2017 10h30 HE
|
2X Oncology, Inc.
CAMBRIDGE, Mass., Aug. 09, 2017 (GLOBE NEWSWIRE) -- 2X Oncology, Inc. ("2X" or the "Company"), a precision medicine company developing targeted therapeutics to address significant unmet needs in...
Living Beyond Breast Cancer to Host 10th Annual Conference on Metastatic Breast Cancer April 8-10
02 févr. 2016 08h50 HE
|
Living Beyond Breast Cancer
PHILADELPHIA, Feb. 2, 2016 (GLOBE NEWSWIRE) -- Hundreds of people will convene here April 8-10, 2016 for the 10th annual Conference on Metastatic Breast Cancer presented by Living Beyond Breast Cancer...
Living Beyond Breast Cancer to post blogs on Metastatic Breast Cancer Awareness Day Oct. 13
08 oct. 2015 15h52 HE
|
Living Beyond Breast Cancer
PHILADELPHIA, Oct. 8, 2015 (GLOBE NEWSWIRE) -- Through Living Beyond Breast Cancer's "Beyond the Breast" campaign, women and men are drawing attention to what it's like to live with metastatic (Stage...
New Metastatic Breast Cancer Resource Available
31 juil. 2015 11h33 HE
|
Patient Advocate Foundation
HAMPTON, Va., July 31, 2015 (GLOBE NEWSWIRE) -- Even with 13,910 new metastatic breast cancer diagnoses each year, Patient Advocate Foundation (PAF), a national nonprofit dedicated to helping...